1-4 of 4
vedolizumab
Close
Sort by
Journal Articles

A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results

Yi-Bin Chen, MD, Nirav N Shah, MD, Anne S. Renteria, MD, Corey S. Cutler, MD MPH, Johan Jansson, PhD, Mona Akbari, MD, Chunlin Chen, MD PhD, Syed Quadri, MD, Andrejus Parfionovas, PhD, Steven Devine
Journal: Blood
Blood (2018) 132 (Supplement 1): 605.
https://doi.org/10.1182/blood-2018-99-111143
Published: 2018
Journal Articles

Anti α4β7 Integrin Monoclonal Antibody (Vedolizumab) for the Treatment of Steroid-Resistant Severe Intestinal Acute Graft Versus Host Disease

Ivetta Danylesko, Roni Shouval, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Arie Apel, MD, Avichai Shimoni, MD, Arnon Nagler, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3263.
https://doi.org/10.1182/blood.V130.Suppl_1.3263.3263
Published: 2017
Journal Articles

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Bader Alahmari, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, Bing Wang, John F DiPersio, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3344.
https://doi.org/10.1182/blood.V128.22.3344.3344
Published: 2016
Journal Articles

Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD

Yngvar Floisand, MDPhD, Knut Lundin, MDPhD, Vladimir Lazarevic, MD, Jorn Dehli Kristiansen, RN, Liv T. N. Osnes, MD PhD, Geir E. Tjonnfjord, MD PhD, Henrik Mikael Reims, MDPhD, Tobias Gedde-Dahl, MDPhD
Journal: Blood
Blood (2015) 126 (23): 3137.
https://doi.org/10.1182/blood.V126.23.3137.3137
Published: 2015